Advertisement

Mammakarzinomrezidiv und metastasiertes Mammakarzinom

  • Eva J. KantelhardtEmail author
  • Martina Vetter
  • Hans-Georg Strauß
Chapter
  • 5 Downloads

Zusammenfassung

Etwa 1/4 der Patientinnen mit diagnostiziertem Mammakarzinom erleiden im Verlauf der Erkrankung trotz adjuvanter Therapie ein Rezidiv. Die Rezidivrate und die Mortalität konnten beim Mammakarzinom in den letzten Jahren durch verbesserte Früherkennung, konsequente adjuvante Chemotherapie, endokrine Therapie sowie die zielgerichteten Substanzen deutlich gesenkt werden. Die Hälfte der Rezidive tritt in den ersten 5 Jahren nach der Operation auf.

Literatur

  1. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O’Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ (2009) Changes in estrogen receptor, progesterone receptor and HER-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 29(5):1557–1562PubMedGoogle Scholar
  2. Butters DJ, Ghersi D, Wilcken N, Kirk SJ, Mallon PT (2010) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 2010(11):CD003368Google Scholar
  3. Carrick S, Ghersi D, Wilcken N, Simes J (2004) Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2004(2):CD003374Google Scholar
  4. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009(2):CD003372PubMedCentralGoogle Scholar
  5. Chlebowski RT, Blackburn GL, Thomson CA et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the women’s intervention nutrition study. J Natl Cancer Inst 98:1767–1776CrossRefPubMedGoogle Scholar
  6. de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJH (2004) Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: A meta-analysis and systematic review. J Clin Oncol 22(19):4010–4018CrossRefPubMedGoogle Scholar
  7. Diel IJ, Body JJ, Lichinitser MR et al (2004) MF 4265 study group: improved quality of life for long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704–1712CrossRefPubMedGoogle Scholar
  8. Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106CrossRefGoogle Scholar
  9. Ford JA, Jones R, Elders A, Mulatero C, Royle P, Sharma P, Stewart F, Todd R, Mowatt G (2012) Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis. Eur J Cancer Aug 17 (Epub ahead of print)Google Scholar
  10. Fossati R, Confalonieri C, Torri V, Ghislandi F, Penna A, Pistotti V (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31500 women. J Clin Oncol 16:3439–3460CrossRefPubMedGoogle Scholar
  11. Geller BM, Kerlikowske K, Carney PA et al (2003) Mammography surveillance following breast cancer. Breast C Res Treatment 81(2):107–115CrossRefGoogle Scholar
  12. Ghersi D, Wilcken N, Simes J, Donoghue E (2005) Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2005(2):CD003366Google Scholar
  13. Gibson L, Lawrence D, Dawson C, Bliss J (2009) Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009(4):CD003370Google Scholar
  14. Holmes MD, Chen WY, Feskanich D et al (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293:2479–2486CrossRefPubMedGoogle Scholar
  15. Ibrahim EM, Al-Homaidh A (2010) Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 28(3):753–765CrossRefPubMedGoogle Scholar
  16. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19(2):343–353CrossRefPubMedGoogle Scholar
  17. Kommission Mamma der AGO e. V. (2011) Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome, 4. Aufl. Zuckschwerdt, MünchenGoogle Scholar
  18. Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie – AGO e. V. (2012) Alle aktuellen Leitlinien. www.ago-online.de/de/fuer-mediziner/leitlinien/Mamma/
  19. Kreienberg R, Kopp I, Lorenz W et al (2008) Interdisziplinäre S3-Leitlinie für die Diagnostik und Therapie des Mammakarzinoms der Frau. 1. Aktualisierung. Zuckschwerdt, MünchenGoogle Scholar
  20. Kroenke CH, Fung TT, Hu FB, Holmes MD (2005) Dietary patterns and survival after breast cancer diagnosis. J Clin Oncol 23(36):9295–9303CrossRefPubMedGoogle Scholar
  21. Kuerer HM (2004) Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: the potential role of partial breast irradiation. Cancer 100(11):2269–2280CrossRefPubMedGoogle Scholar
  22. Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389(10087):2415–2429CrossRefPubMedGoogle Scholar
  23. Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ (2012) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 133(3):831–841CrossRefPubMedGoogle Scholar
  24. McQuay HJ, Collins SL, Carroll D, Moore RA (2004) Radiotherapy for the palliation of painful bone metastases (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester: Wiley (Cochrane Database Syst Rev Issue 2: CD001793)Google Scholar
  25. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799CrossRefPubMedGoogle Scholar
  26. Panet-Raymond V, Truong PT, Alexander C, Lesperance M, McDonald RE, Watson PH (2011) Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence. Cancer 117(10):2035–2043CrossRefPubMedGoogle Scholar
  27. Pavlakis N, Schmidt RL, Stockler MR (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005(3):CD003474Google Scholar
  28. Rauschecker HHF, Clarke MJ, Gatzemeier W, Recht A (2001) Systemic therapy for treating locoregional recurrence in women with breast cancer. Cochrane Database Syst Rev 2001(4):CD002195Google Scholar
  29. Robert Koch-Institut – RKI (2010) Krebs in Deutschland 2007/2008. Häufigkeiten und Trends. Eine gemeinsame Veröffentlichung des Robert Koch-Instituts und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., 8. Aufl. Robert Koch-Institut, BerlinGoogle Scholar
  30. Robson M, Goessl C, Domchek S (2017) Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. N Engl J Med 377(18):1792–1793Google Scholar
  31. Ross JR, Saunders Y, Edmonds PM et al (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327:469–474CrossRefPubMedPubMedCentralGoogle Scholar
  32. Rutgers EJ, van Slooten EA, Kluck HM (1989) Follow-up after treatment of primary breast cancer. Br J Surg 76(2):187–190CrossRefPubMedGoogle Scholar
  33. Schmoor C, Sauerbrei W, Bastert G, Schumacher M (2000) Role of isolatedclocoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 18:1696–1708CrossRefPubMedGoogle Scholar
  34. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21):1446–1452Google Scholar
  35. Slamon DJ, Leyland-Jones B, Shaks S, Fuchs H, Paton V, Bajamonde A (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783–792CrossRefPubMedGoogle Scholar
  36. Sledge GW, Hu P, Falkson G et al (2000) Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an eastern cooperative oncology group study. J Clin Oncol 18:262–266CrossRefPubMedGoogle Scholar
  37. Stockler M, Wilcken N, Ghersi D, Simes RJ (2000) Systematic review of systemic therapie for advanced breast cancer. Cancer Treat Rev 26:168CrossRefGoogle Scholar
  38. Waeber M, Castiglione-Gertsch M, Dietrich D et al (2003) Swiss Group for Clinical Cancer Research (SAKK): adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 14(8):1215–1221CrossRefPubMedGoogle Scholar
  39. Wapnir IL et al (2017) Poor prognosis after second locoregional recurrences in the CALOR trial. Ann Surg Oncol 24(2):398–406Google Scholar
  40. Wilcken N, Hornbuckle J, Ghersi D (2003) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003(2):CD002747Google Scholar
  41. Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 103(3):250–263CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2020

Authors and Affiliations

  • Eva J. Kantelhardt
    • 1
    Email author
  • Martina Vetter
    • 1
  • Hans-Georg Strauß
    • 1
  1. 1.Klinik und Poliklinik für GynäkologieUniversitätsklinikum Halle (Saale)Halle (Saale)Deutschland

Personalised recommendations